Next Article in Journal
Obesity Drug Update: The Lost Decade?
Next Article in Special Issue
GPCR Conformations: Implications for Rational Drug Design
Previous Article in Journal
Allosteric Modulation of αβδ GABAA Receptors
Previous Article in Special Issue
Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2010, 3(11), 3478-3493;

Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease

Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, FL 32610, USA
Author to whom correspondence should be addressed.
Received: 21 September 2010 / Revised: 27 October 2010 / Accepted: 8 November 2010 / Published: 9 November 2010
(This article belongs to the Special Issue GPCR Based Drug Discovery)
Full-Text   |   PDF [307 KB, uploaded 9 November 2010]   |  


Patients with hypertension often manifest a dysregulated renin-angiotensin-aldosterone system (RAAS). Most of the available treatment approaches for hypertension are targeted towards the RAAS including direct renin inhibition, ACE inhibition, angiotensin II type 1 receptor (AT1-R) blockade, and aldosterone receptor antagonism. The Jak2 signaling pathway is intricately coupled to the AT1-R signaling processes involved in hypertension. Here, we review the involvement of Jak2 in the pathogenesis of hypertension, and its potential as a therapeutic target for treatment of AT1-R mediated cardiovascular disease. Jak2 may provide a rational therapeutic approach for patients whose blood pressure is not controlled by standard therapies. View Full-Text
Keywords: angiotensin II; Jak2; AT1-receptor; hypertension angiotensin II; Jak2; AT1-receptor; hypertension

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Kirabo, A.; Sayeski, P.P. Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease. Pharmaceuticals 2010, 3, 3478-3493.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top